Zero patients in the ivermectin group that became hospitalized (as compared to 3 in the control group), the results were overall impressive.
It would be a historically amazing feat of maneuvering bureaucracy, worthy of its own epic book, movie, or perhaps a campfire song, to have wrangled that much data out of those hospitals with highly variable regulations and procedures, nearly all of which are in the U.S. healthcare system.
Reductions in covid-19 deaths and infections may be possible by using ivermectin. Employing ivermectin early on may reduce the number of people progressing to severe disease. The apparent safety and low cost suggest that ivermectin could have an impact on the SARS-CoV-2 pandemic globally.
Ivermectin is an effective treatment for COVID-19. The probability that an ineffective treatment generated results as positive as the 42 studies to date is estimated to be 1 in 4 trillion (p = 0.00000000000023).
Source: ivmmeta.com Figure 1. A. Random effects meta-analysis excluding late treatment. Simplified dosages are shown for comparison, these are the total dose in the first two days
Source: HCQMeta.com HCQ is effective for COVID-19 when used early: meta-analysis of 156 studies (Version 28, December 4, 2020) • HCQ is effective for COVID-19.
Source: Medrxiv View ORCID Profile Amanda Chamieh, Claude Afif, View ORCID Profile Gerard El-Hajj, View ORCID Profile Omar Zmerli, Isabelle Djaffar-Jureidini,View ORCID Profile Roy A. Raad, Raja Ashou, George Juvelekian,View ORCID Profile Jean-Marc Rolain,View ORCID Profile Eid Azar doi: https://doi.org/10.1101/2020.05.28.20114835 This article
